Pharmaceutical News

RSS

Several therapies for hemophilia A, hemophilia B and hemophilia with inhibitors to be launched between 2015-2025

Decision Resources Group forecasts that several therapies will launch for hemophilia A, hemophilia B and hemophilia with inhibitors in the United States and Europe during our 2015-2025 study period.

29 Dec 2015

More than 90% of patients continue to receive prescription opioids after overdose

More than 90 percent of patients with chronic pain continue to receive prescription opioids after an overdose and are at high risk for experiencing a repeated overdose, according to an article published in Annals of Internal Medicine.

29 Dec 2015

FDA approves non-alcoholic Docetaxel Injection

Teikoku Pharma USA, Inc. announced today that the U.S. Food and Drug Administration has approved Docetaxel Injection, Non-Alcohol Formula ("Docetaxel Injection") for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.

29 Dec 2015

PharmAthene to be compensated for loss of profits over SIGA's smallpox antiviral drug

PharmAthene, Inc. announced today that the Delaware Supreme Court affirmed the Delaware Court of Chancery's decision to award PharmAthene lump sum expectation damages for the value of PharmAthene's lost profits for SIGA's smallpox antiviral, Tecovirimat.

26 Dec 2015

Azithromycin remains effective in treatment of urogenital chlamydia, confirms UAB study

In one of the most tightly controlled trials ever conducted of drugs used to treat sexually transmitted infections, researchers at the University of Alabama at Birmingham have confirmed that azithromycin remains effective in the treatment of urogenital chlamydia.

24 Dec 2015

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

Sanofi announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its investigational fixed-ratio combination of insulin glargine 100 Units/mL and lixisenatide, which if approved would be administered as a single daily injection for the treatment of adults with type 2 diabetes.

24 Dec 2015

China leads in pharma sector patent filings among BRIC Nations

With growth rates in developed markets sliding downwards, emerging markets with higher growth rates such as BRIC are expected to be the key drivers of revenue growth for multinational pharma companies. Therefore, multinational pharmaceutical corporations should have a well-planned strategy for each of the BRIC members in order to achieve global prominence.

24 Dec 2015

Researchers identify 124 protein targets of artemisinin in most pathogenic malaria parasite

A team of researchers from the National University of Singapore (NUS) has uncovered the mystery behind the potent parasite-killing effect of artemisinin, a drug that is considered to be the last line of defence against malaria. Given the emergence of artemisinin resistance, these findings could potentially lead to the design of new treatments against drug-resistant parasites.

24 Dec 2015

IASLC lauds FDA approval of alectinib for lung cancer treatment

The International Association for the Study of Lung Cancer (IASLC) is once again gratified to see the approval of a new second-generation lung cancer treatment that can help many patients in their battle against the disease.

24 Dec 2015

ABC/VEN-analysis presents simple and effective method towards rational use of medicines

Rational use of medicines remains to be one of the most challenging problems in health systems worldwide. Kazan Federal University researchers conducted a practical study to assess the impact of introducing evidence-based principles to the practice of medicine procurement in order to manage budget expenditures on medicines of a multidisciplinary health facility for the period of 2011-2014.

23 Dec 2015

NUS scientists uncover mystery behind potent parasite-killing effect of artemisinin

A team of researchers from the National University of Singapore has uncovered the mystery behind the potent parasite-killing effect of artemisinin, a drug that is considered to be the last line of defence against malaria. Given the emergence of artemisinin resistance, these findings could potentially lead to the design of new treatments against drug-resistant parasites.

23 Dec 2015

Drugs approved for various conditions also have antibiotic properties

A number of drugs already approved to treat parasitic infections, cancers, infertility and other conditions also show promise as antibiotic agents against staph and tuberculosis infections, according to a new study by University of Illinois chemists and collaborators. Because these agents act against multiple targets within the bacteria, it may be harder for bacteria to develop resistance.

23 Dec 2015

Evolocumab drug offers no added benefit over appropriate comparator therapy

Evolocumab (trade name: Repatha) has been approved since July 2015 for two therapeutic indications: on the one hand, for hypercholesterolaemia or mixed dyslipidaemia, and on the other, for homozygous familial hypercholesterolaemia.

23 Dec 2015

New footage shows how AIDS vaccine candidate recruits immune cells to destroy infected cells

Using innovative technology, scientists from the Institut Pasteur and Inserm have filmed in vivo the process by which an AIDS vaccine candidate, developed by the French Vaccine Research Institute and the ANRS, triggers the immune response.

23 Dec 2015

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

New research published online today in Blood, the Journal of the American Society of Hematology (ASH), is the first to demonstrate that women on blood thinners can take estrogen-containing contraception or hormone replacement therapy without an increased risk of blood clots or uterine bleeding.

23 Dec 2015

Novel drug shows promise in mouse models of human metastatic breast cancer

A doctor treating a patient with a potentially fatal metastatic breast tumor would be very pleased to find, after administering a round of treatment, that the primary tumor had undergone a change in character - from aggressive to static, and no longer shedding cells that can colonize distant organs of the body. Indeed, most patients with breast and other forms of cancer who succumb to the illness do so because of the cancer's unstoppable spread.

23 Dec 2015

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

The U.S. Food and Drug Administration today approved Zurampic (lesinurad) to treat high levels of uric acid in the blood (hyperuricemia) associated with gout, when used in combination with a xanthine oxidase inhibitor (XOI), a type of drug approved to reduce the production of uric acid in the body.

22 Dec 2015

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

HUYA Bioscience International, Founder, CEO & Executive Chair, Dr. Mireille Gillings today announced that the Ministry of Health, Labour and Welfare granted HBI-8000 orphan drug designation in Japan for peripheral T-cell lymphoma (PTCL).

22 Dec 2015

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

On December 21, the U.S. Food and Drug Administration approved Uptravi (selexipag) tablets to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive, and debilitating rare lung disease that can lead to death or the need for transplantation.

22 Dec 2015

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

Novoron Bioscience, Inc., a private biotech company dedicated to developing new therapeutics for disorders of the central nervous system, today announced that the company has been awarded a National Institutes of Health grant under the Small Business Innovation Research (SBIR) Program.

22 Dec 2015

Pharmaceutical News

Several therapies for hemophilia A, hemophilia B and hemophilia with inhibitors to be launched between 2015-2025

More than 90% of patients continue to receive prescription opioids after overdose

FDA approves non-alcoholic Docetaxel Injection

PharmAthene to be compensated for loss of profits over SIGA's smallpox antiviral drug

Azithromycin remains effective in treatment of urogenital chlamydia, confirms UAB study

Sanofi seeks FDA NDA approval for once-daily fixed-ratio combination of insulin glargine and lixisenatide

China leads in pharma sector patent filings among BRIC Nations

Researchers identify 124 protein targets of artemisinin in most pathogenic malaria parasite

IASLC lauds FDA approval of alectinib for lung cancer treatment

ABC/VEN-analysis presents simple and effective method towards rational use of medicines

NUS scientists uncover mystery behind potent parasite-killing effect of artemisinin

Drugs approved for various conditions also have antibiotic properties

Evolocumab drug offers no added benefit over appropriate comparator therapy

New footage shows how AIDS vaccine candidate recruits immune cells to destroy infected cells

Women suffering from blood clots can safely take hormone replacement therapy with anticoagulants

Novel drug shows promise in mouse models of human metastatic breast cancer

Zurampic (lesinurad) approved to treat high levels of hyperuricemia associated with gout

HBI-8000 granted orphan drug designation in Japan for treatment of peripheral T-cell lymphoma

FDA approves Uptravi tablets to treat adults with pulmonary arterial hypertension

Novoron Bioscience receives NIH grant to study novel therapeutic approach for multiple sclerosis

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Latest News